Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, Kupets R, Smith R, Arrossi S, Bendahhou K. The IARC perspective on cervical cancer screening. N Engl J Med. 2021;385:1908–18.
Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584–90.
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783–91.
Lin S, Gao K, Gu S, You L, Qian S, Tang M, Wang J, Chen K, Jin M. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;127:4030–9.
Haverkos HW, Haverkos GP, O’Mara M. Co-carcinogenesis: human papillomaviruses, coal tar derivatives, and squamous cell cervical cancer. Front Microbiol. 2017;8:2253.
Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, et al. Preventable exposures associated with human cancers. JNCI J Natl Cancer Inst. 2011;103:1827–39.
Gultekin M, Ramirez PT, Broutet N, Hutubessy R. World Health Organization call for action to eliminate cervical cancer globally. Int J Gynecol Cancer. 2020;30:426–7.
Centers for Disease Control and Prevention. Cancers associated with human papillomavirus, United States—2015–2019. USCS Data Brief, no. 32. Atlanta: Centers for Disease Control and Prevention, US Department of Health and Human Services;2022.
Du J, Ahrlund-Richter A, Nasman A, Dalianis T. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008–2018, and perspectives on cancer prevention. Arch Gynecol Obstet. 2021;303:329–35.
Djigma WF, Ouattara AK, Traore IM, Ouedraogo RA, TraorÃ EM, Bado P, Ouedraogo TC, Diarra B, Ilboudo M, Capo-chichi CD. Mapping of fourteen high-risk human papillomavirus genotypes by molecular detection in sexually active women in the West African sub-region. Int J Genet Mol Biol. 2020;12:11–21.
Oyervides-Muñoz MA, Pérez-Maya AA, Sánchez-Domínguez CN, Berlanga-Garza A, Antonio-Macedo M, Valdéz-Chapa LD, Cerda-Flores RM, Trevino V, Barrera-Saldaña HA, Garza-Rodríguez ML. Multiple HPV infections and viral load association in persistent cervical lesions in Mexican women. Viruses. 2020;12:380.
Wang J, Tang D, Wang K, Wang J, Zhang Z, Chen Y, Zhang X, Ma C. HPV genotype prevalence and distribution during 2009–2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination. BMC Womens Health. 2019;19:1–14.
Liu SS, Chan KY, Leung RC, Chan KK, Tam KF, Luk MH, Lo SS, Fong DY, Cheung AN, Lin ZQ, Ngan HY. Prevalence and risk factors of human papillomavirus (HPV) infection in southern Chinese women—a population-based study. PLoS ONE. 2011;6:e19244.
Xiang J, Han L, Fan Y, Feng B, Wu H, Hu C, Qi M, Wang H, Liu Q, Liu Y. Prevalence and genotype distribution of human papillomavirus among attendees at a sexually transmitted diseases clinic in urban Tianjin, China. Int J Gen Med. 2021;14:1983–90.
Li H, Li P, Huang L, Sun L, Ren H, Li P. Prevalence characteristics of cervical human papillomavirus (HPV) infection in the Zhoupu District, Shanghai City, China. Virol J. 2020;17:84.
Ge Y, Zhong S, Ren M, Ge Y, Mao Y, Cao P. Prevalence of human papillomavirus infection of 65,613 women in East China. BMC Public Health. 2019;19:178.
Ma L, Lei J, Ma L, Cong X, Wang N, Yang H, Liu Q, Yu Y, Cao Y. Characteristics of women infected with human papillomavirus in a tertiary hospital in Beijing China, 2014–2018. BMC Infect Dis. 2019;19:670.
Yu H, Yi J, Dou YL, Chen Y, Kong LJ, Wu J. Prevalence and genotype distribution of human papillomavirus among healthy females in Beijing, China, 2016–2019. Infect Drug Resist. 2021;14:4173–82.
Guo C, Du H, Belinson JL, Wang C, Huang X, Qu X, Wu R. Team C: The prevalence and distribution of human papillomavirus among 10,867 Chinese Han women. Infect Agent Cancer. 2021;16:21.
Zhang J, Zhao Y, Dai Y, Dang L, Ma L, Yang C, Li Y, Kong L, Wei L, Zhang S, et al. Effectiveness of high-risk human papillomavirus testing for cervical cancer screening in China: a multicenter, open-label, randomized clinical trial. JAMA Oncol. 2021;7:263–70.
Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J, Zhao W, Li D, Liu H, Hao M. Prevalence, genotype distribution and risk factors of cervical HPV infection in Yangqu, China: a population-based survey of 10086 women. Hum Vaccin Immunother. 2020;16:1645–52.
Xue H, Lin X, Li T, Yan X, Guo K, Zhang Y. Prevalence and genotype distribution of human papillomavirus infection in asymptomatic women in Liaoning province, China. J Med Virol. 2015;87:1248–53.
Wang X, Ji Y, Li J, Dong H, Zhu B, Zhou Y, Wang J, Zhou X, Wang Y, Peppelenbosch MP, et al. Prevalence of human papillomavirus infection in women in the autonomous region of inner Mongolia: a population-based study of a Chinese ethnic minority. J Med Virol. 2018;90:148–56.
Chen X, Wallin KL, Duan M, Gharizadeh B, Zheng B, Qu P. Prevalence and genotype distribution of cervical human papillomavirus (HPV) among women in urban Tianjin, China. J Med Virol. 2015;87:1966–72.
Luo G, Sun X, Li M, Liu T, Hu G, He Y, Mao L, Yan L, Xie L, Zou H, Luo X. Cervical human papillomavirus among women in Guangdong, China 2008–2017: implication for screening and vaccination. J Med Virol. 2019;91:1856–65.
Lin W, Zhang Q, Chen Y, Chen L, Dong B, Sun P. The prevalence of human papillomavirus and bacterial vaginosis among young women in China: a cross-sectional study. BMC Womens Health. 2021;21:409.
Wei F, Yin K, Wu X, Lan J, Huang S, Sheng W, Zhao J, Su Y, Wang Y, Li Y, et al. Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study. Emerg Microbes Infect. 2016;5:e119.
Han X, Song G, Li Y, Dong Z, Yan X, Wang S, Tian H, Wu X, Li C, Huo Y. Prevalence and genotype distribution of human papillomavirus infection among women aged 30–65 years in Xi’an, China: a population-based study of 14,655 women. Hum Vaccin Immunother. 2021;17:5439–46.
He L, He J. Distribution of high-risk HPV types among women in Sichuan province, China: a cross-sectional study. BMC Infect Dis. 2019;19:390.
Luo Q, Jiang N, Wu Q, Wang J, Zhong J. Prevalence and genotype distribution of HPV and cervical pathological results in Sichuan Province, China: a three years surveys prior to mass HPV vaccination. Virol J. 2020;17:100.
Liu J, Ma S, Qin C, Zheng S, Chen Z, Huang Y, Xiong J, Huo Y. Prevalence and genotype distribution of human papillomavirus in Zhengzhou, China, in 2016. Arch Virol. 2020;165:731–6.
Li L, Zheng Z, Li L. Evaluation of human-papillomavirus screening for cervical cancer in China’s rural population. PeerJ. 2019;7:e8152.
Gao B, Liou YL, Yu Y, Zou L, Li W, Huang H, Zhang A, Xu D, Zhao X. The characteristics and risk factors of human papillomavirus infection: an outpatient population-based study in Changsha, Hunan. Sci Rep. 2021;11:15128.
Wang L, Yu C, Ni X, Wang F, Wen C, Jin M, Chen J, Zhang K, Wang J. Prevalence characteristics of human papillomavirus (HPV) infection among women receiving physical examinations in the Shangcheng District, Hangzhou city, China. Sci Rep. 2021;11:16538.
Yan X, Shen L, Xiao Y, Wang Q, Li F, Qian Y. Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016–2020. Virol J. 2021;18:208.
Li J, Zhao C, Wu R, Li M, Zhao Y, Du H, Li L, Lin Z, Zhang Z, Wei L. Characteristics of genotypes and prevalence of high-risk human papillomavirus in different economic development regions in China. J Infect. 2022;85:174–211.
Wang R, Guo XL, Wisman GB, Schuuring E, Wang WF, Zeng ZY, Zhu H, Wu SW. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis. 2015;15:257.
Wang X, Han S, Li X, Wang X, Wang S, Ma L. Prevalence and distribution of human papillomavirus (HPV) in Luoyang city of Henan province during 2015–2021 and the genetic variability of HPV16 and 52. Virol J. 2022;19:37.
Jin R, Qian H, Zhang Y, Yuan D, Bao J, Zhou H, Chen M, Huang J, Yu H. The prevalence and genotype distribution of human papillomaviruses among women in Taizhou, China. Medicine (Baltimore). 2019;98:e17293.
Wu C, Zhu X, Kang Y, Cao Y, Lu P, Zhou W, Zhou H, Zhang Y, Song Y. Epidemiology of human papilloma virus infection among women in Fujian, China. BMC Public Health. 2017;18:95.
Xing J, Tan T, Guo YL, Zhu JQ, Zheng AW, Yu AJ, Niu Z. Heat maps present the spatial distribution of human papillomavirus infection in Zhejiang Province, China. Oncol Lett. 2021;21:366.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.
Byun JM, Jeong DH, Kim YN, Jung EJ, Lee KB, Sung MS, Kim KT. Persistent HPV-16 infection leads to recurrence of high-grade cervical intraepithelial neoplasia. Medicine (Baltimore). 2018;97:e13606.
Schiffman M, Doorbar J, Wentzensen N, de Sanjose S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.
Kim M, Park NJ, Jeong JY, Park JY. Multiple human papilloma virus (HPV) infections are associated with HSIL and persistent HPV infection status in Korean patients. Viruses. 2021;13:1342.
de Sanjose S, Brotons M, Pavon MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13.
Schiffman M, Saraiya M. Control of HPV-associated cancers with HPV vaccination. Lancet Infect Dis. 2017;17:6–8.
Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, Sawata M, Tanaka Y. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: a randomized, phase 3, placebo-controlled study. Vaccine. 2019;37:1651–8.
Zhang X, Chen H, Zhou J, Huang Q, Feng XY, Li J. Impact of web-based health education on HPV vaccination uptake among college girl students in Western and Northern China: a follow-up study. BMC Womens Health. 2022;22:46.
Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang SJ, Zhao FH, Li MQ, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020;112:145–53.
Liu Y, Di N, Tao X. Knowledge, practice and attitude towards HPV vaccination among college students in Beijing, China. Hum Vaccin Immunother. 2020;16:116–23.
You D, Han L, Li L, Hu J, Zimet GD, Alias H, Danaee M, Cai L, Zeng F, Wong LP. Human papillomavirus (HPV) vaccine uptake and the willingness to receive the HPV vaccination among female college students in china: a multicenter study. Vaccines (Basel). 2020;8:31.
Deng C, Chen X, Liu Y. Human papillomavirus vaccination: coverage rate, knowledge, acceptance, and associated factors in college students in mainland China. Hum Vaccin Immunother. 2021;17:828–35.
Wei L, Xie X, Liu J, Qiao Y, Zhao F, Wu T, Zhang J, Ma D, Kong B, Chen W, et al. Elimination of cervical cancer: challenges promoting the HPV vaccine in China. Indian J Gynecol Oncol. 2021;19:51.
Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23.
Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307:693–703.